作者及服务介绍 - 文章作者Terry Chrisomalis运营名为Biotech Analysis Central的医药服务，该服务提供对多家医药公司的深度分析 [1] - Biotech Analysis Central服务在Seeking Alpha平台的订阅价格为每月49美元，年度计划可享受3350%的折扣，价格为每年399美元 [1] - 作者所属的投资小组Biotech Analysis Central拥有一个包含600多篇生物技术投资文章的资料库，以及一个包含10多只中小盘股票的投资组合模型 [2] 公司历史关联 - 作者此前曾撰写关于Inhibrx Biosciences Inc的文章，题为"Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi" [2]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...